Age-related changes in the parameters of cellular immunity, the activity of intracellular lymphocyte dehydrogenases and functional activity of neutrophils in children with Gaucher disease

Cover Page

Cite item

Full Text

Abstract

   Gaucher disease (GD) is an autosomal recessively inherited disease that belongs to the group of lysosomal storage diseases. In GD, there is chronic activation of the macrophage system, disruption of the regulatory functions of macrophages, a shift in cytokine regulation towards pro-inflammatory cytokines and the development of chronic inflammation involving all immune cells, which can lead to changes in the composition of both major and minor populations of lymphocytes. Reduced beta-glucocerebrosidase activity impairs normal lysosomal function and autophagy, leading to the intracellular accumulation of glycosphingolipids, creating a self-sustaining cycle of impaired glucocerebroside utilization with the aggravation of both lysosomal and mitochondrial functions. It is known that untreated patients with GD are susceptible to more frequent and complicated infectious diseases, which presumably may arise due to changes in the functional activity of neutrophils caused by the disruption of the process of phagocytosis and oxidative burst in this cell population.

   The aim: to study the age-related features of the composition of the major and minor populations of peripheral blood lymphocytes, the activity of intracellular dehydrogenases of lymphocytes and the functional activity of neutrophils in children with GD.

   The study was approved by the Independent Ethics Committee and the Scientific Council of the National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation. The study included 73 children with GD, of which 26 children were examined at different age periods (1 child – 4 tests, 3 children – 3 tests, 22 children – 2 tests), the comparison group consisted of 148 healthy children comparable in age. The determination of the subpopulation composition of lymphocytes, the study of succinate dehydrogenase activity in the major and minor populations of lymphocytes (by immunocytochemical method) and the assessment of the functional activity of neutrophils were carried out using flow cytometry. The parameters of lymphocyte subpopulations were analyzed as percentage deviations from the age norm. The activity of intracellular dehydrogenases (succinate dehydrogenase, NADH dehydrogenase, lactate dehydrogenase) was determined by a cytomorphodensitometric method using image analysis. The statistical calculations were performed using the Statistica 10.0 program (StatSoft, USA). A decrease in NK cells and an increase in Th17 cells and activated T helper cells are usually observed in children with GD with age. The analysis of the activity of intracellular dehydrogenases revealed a decrease in the processes of oxidative phosphorylation and glycolysis in peripheral blood lymphocytes in children with GD. The functional activity of neutrophils in the majority of children with GD corresponded to the reference values.

About the authors

O. V. Kurbatova

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: putintseva@mail.ru
ORCID iD: 0000-0002-9213-5281

Olga V. Kurbatova, Cand. Med. Sci., a senior researcher, Head of the Laboratory

Laboratory of Experimental Immunology and Virology

119991; 2, building 1, Lomonosovskiy Avenue; Moscow

Russian Federation

G. B. Movsisyan

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Email: gongurik@mail.ru
ORCID iD: 0000-0003-2881-4703

Moscow

Russian Federation

M. V. Konyashin

The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Email: matele99@mail.ru
ORCID iD: 0009-0004-3206-8090

Moscow

Russian Federation

S. V. Petrichuk

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Email: cito@list.ru
ORCID iD: 0000-0003-0896-6996

Moscow

Russian Federation

D. G. Kuptsova

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Email: cito@list.ru
ORCID iD: 0000-0001-7771-3314

Moscow

Russian Federation

T. V. Radygina

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Email: darinka_83@mail.ru
ORCID iD: 0000-0003-4704-6885

Moscow

Russian Federation

E. L. Semikina

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation; The I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (the Sechenov University)

Email: semikinaelena@yandex.ru
ORCID iD: 0000-0001-8923-4652

Moscow

Russian Federation

A. S. Potapov

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation; The I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (the Sechenov University)

Email: gongurik@mail.ru
ORCID iD: 0000-0003-4905-2373

Moscow

Russian Federation

A. P. Fisenko

National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation

Email: director@nczd.ru
ORCID iD: 0000-0001-8586-7946

Moscow

Russian Federation

References

  1. Stone W.L., Basit H., Mukkamalla S.K.R., Master S.R. Gaucher Disease. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023.
  2. Futerman A.H., Zimran A. (eds.). Gaucher Disease. Taylor & Francis Group, LLC; 2007. 528 p.
  3. Lukina E.A., Sysoeva E.P., Mamonov V.E., Yatsyk G.A., Tsvetaeva N.V., Gundobina O.S. et al. National clinical guidelines “Diagnosis and treatment of Gaucher disease”. Moscow; 2014, p 21. (In Russ.)
  4. Federal clinical guidelines for the provision of medical care for children with Gaucher disease. Moscow: the Union of Pediatricians of Russia; 2015, p 16. (In Russ.)
  5. Federal clinical guidelines for the provision of medical care for children with Gaucher disease. Moscow: the Union of Pediatricians of Russia; 2021, p 16. [Electronic resource] URL: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy/%D0%91%D0%BE%D0%BB%D0%B5%D0%B7%D0%BD%D1%8C%20%D0%93%D0%BE%D1%88%D0%B5_1.06.2021.pdf (access date 07. 02. 2024. (In Russ.)
  6. Davydova A.V. Lysosomal storage disorders: Gaucher's disease. Siberian medical journal (Irkutsk) 2009; 88 (5): 9–14. (In Russ.)
  7. Movsisyan G.B., Savost`yanov K.V., Pushkov A.A., Mazanova N.N., Khazykova J.V., Firumyants А.I., et al. Velaglucerase alfa for treatment in children with Gaucher disease type 1: the Russian experience. Pediatric Hematology/Oncology and Immunopathology 2023; 22 (3): 94–102. doi: 10.24287/1726-1708-2023-22-3-94-102 (In Russ.)
  8. Bukina T.M., Basistova A.А., Belogurova M.B., Gundobina O.S. Gaucher disease: pathogenesis and clinical manifestations. Pediatric Hematology/Oncology and Immunopathology 2004; 3 (4): 36–42. (In Russ.)
  9. Belogurova M.B. Pathogenesis, clinical manifestation, diagnosis, and treatment of Gaucher's disease. Pediatric Hematology/Oncology and Immunopathology 2008; 7 (4): 11–17. (In Russ.)
  10. Ponomarev R.V., Lukina E.A. Gaucher disease: achievements and prospects. Therapeutic Archive 2021; 93 (7): 830–6. doi: 10.26442/00403660.2021.07.200912 (In Russ.)
  11. Belogurova M.B., Dinikina Yu.V., Kudlay D.A., Borozinets A.Yu. Gaucher disease in children: what has changed in the 21st century. Russian Journal of Pediatric Hematology and Oncology 2019; 6 (4): 19–24. doi: 10.21682/2311-1267-2019-6-4-19-24 (In Russ.)
  12. Zahran A.M., Saad K., Abo-Elela M.G., Eloseily E.M., Gad E.F., Elgheet A.M.A., et al. Down-regulation of Regulatory T-cells in Children With Gaucher Disease Under Enzyme Replacement Therapy. Clin Appl Thromb Hemost 2019; 25: 1076029619889685. doi: 10.1177/1076029619889685
  13. Zahran A.M., Saad K., Elsayh K.I., Abdou M.A.A., Abo-Elgheet A.M., Eloseily E.M., et al. Upregulation of Cytotoxic T-cells in pediatric patients with Gaucher disease. Sci Rep 2022; 12 (1): 4977. doi: 10.1038/s41598-022-08843-4
  14. Zahran A.M., Youssef M.A.M., Shafik E.A., Zahran Z.A.M., El-Badawy O., Abo Elgheet A.M., Elsayh K.I. Downregulation of B regulatory cells and upregulation of T helper 1 cells in children with Gaucher disease undergoing enzyme replacement therapy. Immunol Res 2020; 68 (2): 73–80. doi: 10.1007/s12026-020-09129-5
  15. Klein A.D., Outeiro T.F. Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria. Nat Commun 2023; 14 (1): 6383.
  16. Baden P., Perez M.J., Raji H., Bertoli F., Kalb S., Illescas M., et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun 2023; 14 (1): 1930. doi: 10.1038/s41467-023-37454-4
  17. Kurbatova O.V., Petrichuk S.V., Kuptsova D.G., Radygina T.V., Semikina E.L., Potapov A.S. Age-related features of subpopulation composition and lymphocyte metabolism in children with Wilson–Konovalov disease. Kremlin Medicine Journal 2023; 2: 5–11. doi: 10.48612/cgma/a5rx-evxd-xkk9 (In Russ.)
  18. Kurbatova O.V., Izmailova T.D., Surkov A.N., Namazova-Baranova L.S., Polyakova S.I., Miroshkina L.V., et al. Mitochondrial dysfunction in children with hepatic forms of glycogen storage disease. Annals of the Russian academy of medical sciences 2014; 69 (7–8): 78–84. doi: 10.15690/vramn.v69i7-8.1112 (In Russ.)
  19. Giraldo P., Alfonso P., Irún P., Gort L., Chabás A., Vilageliu L., et al. Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Orphanet J Rare Dis 2012; 7 (1): 17. doi: 10.1186/1750-1172-7-17
  20. Nalysnyk L., Rotella P., Simeone J.C., Hamed A., Weinreb N. Gaucher disease epidemiology and natural history : a comprehensive review of the literature. Hematology 2017; 22 (2): 65–73. doi: 10.1080/10245332.2016.1240391
  21. Degterev M.B., Smolov M.A., Vishnevskiy A.Yu., Shukurov R.R. Physico-chemical characterization of imiglucerase bio-analogous and reference preparation by mass spectrometric methods. In: Biotechnology: state and development prospects. Proceedings of the International Congress. Moscow; 2019. Pp. 302–303. (In Russ.)
  22. Sysoeva E.P., Ponomarev R.V., Lukina K.A., Chavynchak R.B., Korotkova S.B., Zhilyaeva M.V., еt al. Evaluation of the effectiveness and safety of the biosimilar drug Glurazym (imiglucerase) in patients with type I Gaucher disease. Gematologiya i transfuziologiya 2020; 65 (1): 8–23. (In Russ.)
  23. Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., et al. Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers. Oncohematology 2019; 14 (4): 73–83. doi: 10.17650/1818-8346-2019-14-4-73-83 (In Russ.)
  24. Petrichuk S.V., Izmailova T.D., Radygina T.V. Method for measuring the mitochondrial activity of lymphocytes. Patent for invention RU 2302635 C1, 10.07.2007. Application No. 2005141145/15 dated 12/28/2005. (In Russ.)
  25. Highton A.J., Schuster I.S., Degli-Esposti M.A., Altfeld M. The role of natural killer cells in liver inflammation. Semin Immunopathol 2021; 43 (4): 519–33. doi: 10.1007/s00281-021-00877-6
  26. Pandey M.K., Rani R., Zhang W., Setchell K., Grabowski G.A. Immunological cell type characterization and Th1–Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab 2012; 106 (3): 310–22. doi: 10.1016/j.ymgme.2012.04.020
  27. Wilson A.N., Mosure S.A., Solt L.A. A Compass to Guide Insights into Th17 Cellular Metabolism and Autoimmunity. Immunometabolism. 2022; 4 (1): e220001. doi: 10.20900/immunometab20220001

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Kurbatova O.V., Movsisyan G.B., Konyashin M.V., Petrichuk S.V., Kuptsova D.G., Radygina T.V., Semikina E.L., Potapov A.S., Fisenko A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.